Zevalin
Aug 02, 2018
GeneDx secures $92M funding; BioTech Innovations partners with Novartis for R&D collaboration
Sutro Biopharma nets $85.4M to drive antibody-drug conjugates Sutro Biopharma reeled in an $85.4 million series E that will advance some early-stage programs as well as its cancer pipeline, which includes a pair of antibody-drug conjugates (ADCs).Of its ADC assets, STRO-001 is in phase 1 for lymphoma and multiple my...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
